vs
Side-by-side financial comparison of INSEEGO CORP. (INSG) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $48.4M, roughly 1.2× INSEEGO CORP.). INSEEGO CORP. runs the higher net margin — 1.0% vs -83.0%, a 83.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 0.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 13.6%).
Inseego Corp designs, manufactures and delivers advanced 5G and IoT solutions including mobile hotspots, edge computing devices, and cloud-based device management platforms. It primarily serves telecom operators, enterprise clients, and public sector customers across global markets.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
INSG vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $57.3M |
| Net Profit | $469.0K | $-47.5M |
| Gross Margin | 42.2% | 91.6% |
| Operating Margin | 2.7% | -82.2% |
| Net Margin | 1.0% | -83.0% |
| Revenue YoY | 0.6% | 36.9% |
| Net Profit YoY | 182.9% | -9.6% |
| EPS (diluted) | $-0.02 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $57.3M | ||
| Q3 25 | $45.9M | $51.3M | ||
| Q2 25 | $40.2M | $48.5M | ||
| Q1 25 | $31.7M | $32.7M | ||
| Q4 24 | $48.1M | $41.8M | ||
| Q3 24 | $54.0M | $33.3M | ||
| Q2 24 | $51.6M | $29.1M | ||
| Q1 24 | $37.5M | $26.0M |
| Q4 25 | $469.0K | $-47.5M | ||
| Q3 25 | $1.4M | $-52.9M | ||
| Q2 25 | $507.0K | $-46.6M | ||
| Q1 25 | $-1.6M | $-49.5M | ||
| Q4 24 | $-566.0K | $-43.3M | ||
| Q3 24 | $9.0M | $-43.6M | ||
| Q2 24 | $624.0K | $-32.3M | ||
| Q1 24 | $-4.5M | $-141.4M |
| Q4 25 | 42.2% | 91.6% | ||
| Q3 25 | 41.6% | 89.3% | ||
| Q2 25 | 41.1% | 88.6% | ||
| Q1 25 | 47.3% | 88.8% | ||
| Q4 24 | 37.3% | 90.9% | ||
| Q3 24 | 34.8% | 88.5% | ||
| Q2 24 | 36.4% | 89.9% | ||
| Q1 24 | 35.3% | 89.2% |
| Q4 25 | 2.7% | -82.2% | ||
| Q3 25 | 4.7% | -102.6% | ||
| Q2 25 | 3.2% | -93.4% | ||
| Q1 25 | -1.3% | -143.7% | ||
| Q4 24 | 3.7% | -98.6% | ||
| Q3 24 | 1.9% | -132.0% | ||
| Q2 24 | 3.6% | -139.2% | ||
| Q1 24 | -7.9% | -538.7% |
| Q4 25 | 1.0% | -83.0% | ||
| Q3 25 | 3.1% | -103.1% | ||
| Q2 25 | 1.3% | -96.1% | ||
| Q1 25 | -5.0% | -151.4% | ||
| Q4 24 | -1.2% | -103.6% | ||
| Q3 24 | 16.6% | -131.2% | ||
| Q2 24 | 1.2% | -110.9% | ||
| Q1 24 | -11.9% | -544.4% |
| Q4 25 | $-0.02 | $-0.73 | ||
| Q3 25 | $0.03 | $-0.82 | ||
| Q2 25 | $-0.03 | $-0.75 | ||
| Q1 25 | $-0.16 | $-0.81 | ||
| Q4 24 | $0.62 | $-0.71 | ||
| Q3 24 | $-0.06 | $-0.73 | ||
| Q2 24 | $-0.02 | $-0.55 | ||
| Q1 24 | $-0.44 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-4.0M | $139.1M |
| Total Assets | $93.8M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $388.9M | ||
| Q3 25 | $14.6M | $416.1M | ||
| Q2 25 | $13.2M | $291.0M | ||
| Q1 25 | $35.1M | $314.5M | ||
| Q4 24 | $39.6M | $320.6M | ||
| Q3 24 | $12.0M | $298.4M | ||
| Q2 24 | $49.0M | $319.1M | ||
| Q1 24 | $12.3M | $201.2M |
| Q4 25 | $-4.0M | $139.1M | ||
| Q3 25 | $-7.7M | $148.8M | ||
| Q2 25 | $-10.5M | $-11.9M | ||
| Q1 25 | $-13.0M | $18.9M | ||
| Q4 24 | $-12.9M | $21.7M | ||
| Q3 24 | $-85.1M | $11.2M | ||
| Q2 24 | $-101.8M | $39.3M | ||
| Q1 24 | $-105.6M | $61.6M |
| Q4 25 | $93.8M | $480.2M | ||
| Q3 25 | $85.8M | $506.9M | ||
| Q2 25 | $83.1M | $372.7M | ||
| Q1 25 | $93.0M | $386.7M | ||
| Q4 24 | $100.0M | $392.3M | ||
| Q3 24 | $113.4M | $363.6M | ||
| Q2 24 | $149.6M | $381.8M | ||
| Q1 24 | $122.1M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.0M | $-25.4M |
| Free Cash FlowOCF − Capex | $11.6M | — |
| FCF MarginFCF / Revenue | 24.0% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | 25.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.0M | $-25.4M | ||
| Q3 25 | $3.2M | $-26.6M | ||
| Q2 25 | $-4.5M | $-23.3M | ||
| Q1 25 | $-3.5M | $-40.4M | ||
| Q4 24 | $-14.2M | $-18.8M | ||
| Q3 24 | $14.8M | $-25.2M | ||
| Q2 24 | $27.6M | $-29.1M | ||
| Q1 24 | $5.2M | $-40.7M |
| Q4 25 | $11.6M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $-4.7M | — | ||
| Q1 25 | $-3.5M | — | ||
| Q4 24 | $-14.3M | — | ||
| Q3 24 | $14.8M | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | 24.0% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | -11.6% | — | ||
| Q1 25 | -11.0% | — | ||
| Q4 24 | -29.7% | — | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | 53.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 25.50× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | -8.81× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 44.31× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
